Impel Neuropharma, Inc. is a Pennsylvania Foreign Business Corporation filed On April 4, 2019. Business Outlook. Recommend. Impel, POD, TRUDHESA, and the Impel and Trudhesa Logos are trademarks of Impel NeuroPharma, Inc. 201 Elliott Avenue West, Suite 260 Impel NeuroPharma Inc. is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier (BBB) using direct nose-to-brain delivery. EquityZen does not have an affiliation with, formal relationship with, or endorsement from Impel NeuroPharma or any companies feature above. The Registered Agent on file for this company is National Registered Agents, Inc.. All rights reserved. All content is posted anonymously by employees working at Impel NeuroPharma. Abstract: A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. Private Company. 66.3% of Patients Reported Pain Relief Within Two Hours of Treatment of Acute Migraine. 8/9/2021. Impel NeuroPharma Pulls In $67.5M. Impel NeuroPharma Announces Pricing of $80.0 Million Initial Public Offering. This is the Impel NeuroPharma company profile. Life science firms venBIO, 5AM Ventures and Vivo Capital made investments in the round. Phone screen with Mgr followed by Panel interview. We are quality driven, efficient and agile. Announce Phase 2 topline results, 2022Initiate INP107 PK study for pivotal dose selection, Initiate Phase 2 proof-of-concept clinical trial, Initiate INP107 PK study for pivotal dose selection, 1 Expected PDUFA date informed by FDA guidance. We have an unwavering commitment to improving patients’ lives. October 5, 2015. Patient Centricity. CEO Approval. We are champions of bold thinking and disruptive technologies. Impel NeuroPharma Overview. Impel NeuroPharma’s mission is to create transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the CNS. While an ideal target for drug delivery, to date no technology has been able to consistently deliver drugs predictably and consistently to the upper nasal area. As a result, Impel NeuroPharma’s therapies have the potential to improve the onset of symptomatic … All rights reserved. Impel NeuroPharma devices. INP104 aims to optimize dihydroergotamine mesylate (DHE) for fast and lasting whole migraine relief, regardless of when in the migraine attack it is administered, without an injection. The POD devices are designed to deliver a range of therapeutic molecules and formulations deep into the vascular rich upper nasal space. Impel NeuroPharma, Inc., is a privately held, Seattle-based biopharmaceutical company which, based on the research of its founder, Chief Scientific Officer John … The upper nasal space is surrounded by a rich vasculature that has the potential for injection-like absorption, resulting in more rapid and consistent bioavailability and clinical response. Seattle, WA 98119. Motivated team members. Impel NeuroPharma is currently developing INP104 with the goal to be a transformative new therapy for acute migraine. I interviewed at Impel NeuroPharma (Seattle, WA) in Jan 2016. Impel Neuropharma. Our investigational therapies are enabled by the … Though small, the company is loaded with folks who are passionate, respectful, and motivated. 8 Age (years) $60.0M Total Funding. The study met its primary objectives, with no new safety signals or concerning trends in … 2H:2022 Today, Impel NeuroPharma is developing treatments that use this gateway to deliver therapies for patients living with CNS disorders with high unmet medical needs. Impel NeuroPharma's proprietary POD™ intranasal drug delivery device is designed to deliver drugs to the richly-vascularized upper nasal cavity to achieve superior biodistribution and bioavailability of both small molecules and biologic drugs. © 2021 Impel NeuroPharma, Inc., Seattle, WA. As a result, Impel NeuroPharma’s therapies have the potential to improve the onset of symptomatic relief for a spectrum of neurological conditions. Phone: 206.568.1466 SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for…, TRUDHESA Is the First and Only Therapeutic to Use POD technology to Deliver Dihydroergotamine Mesylate (DHE) to the Vascular-Rich Upper…, TRUDHESA™ New Drug Application (NDA) Under Review by U.S. Food & Drug Administration (FDA) with PDUFA Target Action Date of September…, acute agitation associated with schizophrenia, Impel NeuroPharma Announces Launch of Proposed Public Offering, Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine, IMPEL NEUROPHARMA ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE, 2020 American Headache Society (AHS) Virtual Annual Scientific Meeting, 30th Anniversary Headache Cooperative of New England Winter Headache Symposium – 28-29 FEB, 33rd Annual Practicing Physician’s Approach to the Difficult Headache Patient – 14-17 FEB. About Impel NeuroPharma Impel NeuroPharma, Inc., is a privately-held, Seattle -based company devoted to creating life-changing, innovative therapies for … Impel NeuroPharma, Inc. is a privately held, Seattle-based biopharmaceutical company focused on developing transformative therapies for people living with … By Mark Terry . We are inspired, resilient and seek to cultivate hope. 3M announced that it is helping Impel Neuoropharma develop its Precision Olfactory Delivery for delivery of neurological drugs into the brain and … Impel NeuroPharma is focused on developing transformative therapies for people living with central nervous system (CNS) disorders through the pioneering of an optimized approach to drug delivery. SEATTLE, Dec. 6, 2018 /PRNewswire/ -- Impel NeuroPharma ("Impel" or the "Company"), a Seattle … It was co-led by KKR and Northwest Venture Partners.Existing investors Vivo Capital, 5AM Ventures and venBio Partners also participated.. All rights reserved. Impel NeuroPharma is investigating utilizing its performance technology to deliver proven treatments for neurological conditions, including migraine, OFF episodes in Parkinson’s disease and acute agitation associated with schizophrenia, bipolar I disorder and autism. SEATTLE, WA, Impel NeuroPharma announces $67.5 million Series D funding round. 07 Apr 2021 Impel NeuroPharma announces intention to initiate phase II proof of concept clinical trial in Agitation in 2021 (Impel NeuroPharma pipeline, April 2021) 28 Mar 2021 No recent reports of development identified for phase-I development in Agitation … The money will be used to speed the clinical development of its existing portfolio for central nervous system (CNS) disorders. © 2021 Impel NeuroPharma, Inc., Seattle, WA. Washington salaries - 1 salaries reported. The POD devices are designed to deliver a range of therapeutic molecules and formulations deep into the vascular rich upper nasal space. $65,176 / yr. Quality Manager salaries - 1 salaries reported. Our investigational therapies are enabled by the Company’s proprietary upper nasal delivery technology, known as the Precision Olfactory Delivery, or POD®, device. Impel NeuroPharma, Inc. is a privately held, Seattle-based biopharmaceutical company focused on developing transformative therapies for people living with … Impel Neuropharma is the first company to investigate targeting the upper nasal space with optimized therapeutic molecules and formulations for treating CNS diseases. October 1, 2015. Based in Seattle, WA, Impel NeuroPharma is a small health care company with only 75 employees and an annual revenue of $8.5M. Pros. Impel NeuroPharma’s proprietary (POD) device technology enables entirely new categories of drugs, including biologics, to be administered using a … Impel NeuroPharma is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. Impel NeuroPharma, Inc., is a privately-held, Seattle -based biotechnology company devoted to creating life-changing, innovative therapies for central nervous system (CNS) diseases. Interview. New Line of 3M Respirator Cartridges Visually Indicates End of Service Life in Certain Environments to Help Protect Users Against Hazardous Vapors. Impel, POD, TRUDHESA, and the Impel and Trudhesa Logos are trademarks of Impel NeuroPharma, Inc. 201 Elliott Avenue West, Suite 260 Impel NeuroPharma (2) Done Salary Salary filter options. Oct 5, 2017. 201 Elliott Avenue West, Suite 260 Seattle, WA 98119. Seattle-based Impel will get $21 million upfront and $15 million after it reaches development and… Dec 15, 2017 - Anonymous Employee in Seattle, WA. This unique combination has the potential to deliver consistent and predictable doses of drug, potentially enabling on-demand access for molecules previously limited to injection and hospital-based use. Impel NeuroPharma to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021. Multiple clinical trials have demonstrated that Impel NeuroPharma’s therapies have the potential to deliver injection-like absorption, as well as predictable and consistent drug delivery via our proprietary POD drug delivery technology.1. The money will be used to speed the clinical development of its existing portfolio for central nervous system (CNS) disorders. Impel NeuroPharma is focused on developing transformative therapies for people living with central nervous system (CNS) disorders through the pioneering of an optimized approach to drug delivery. Assignee: IMPEL NEUROPHARMA, INC. Impel Neuropharma Inc. Impel Neuropharma, Inc. operates as a bio-pharmaceutical company. Impel's products utilize its novel, nasal drug-delivery Precision Olfactory Delivery, or POD™, device technology to deliver liquid or dry powder forms of drug to the upper nasal cavity in a consistent and predictable manner. IMPEL, POD and the IMPEL Logo are trademarks of Impel NeuroPharma, Inc. Cons. Innovation is our passion. Impel NeuroPharma presented patient-reported outcomes data from the Company’s pivotal Phase 3, open-label study “STOP 301” of INP104. © 2021 Impel NeuroPharma, Inc., Seattle, WA. Date of Patent: May 18, 2021. Salary. Location filter options. Seattle, WA 98119. Inventors: John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford. Impel NeuroPharma’s pipeline is built upon its proprietary Precision Olfactory Delivery, or POD®, upper nasal drug delivery technology, which is paired with specific formulations of proven and effective therapeutic molecules. Impel NeuroPharma Inc. said today that it closed a $36 million series C financing round to fund its pipeline of precision olfactory delivery (POD) intranasal devices. INP104 (Dihydroergotamine) — Phase 3 completed, INP107 (Levodopa/Carbidopa) — Phase 1 completed, By YE:2021Initiate Phase 2 proof-of-concept clinical trial Job Title. Impel NeuroPharma has named John Congleton president and CEO. Everyone seened very positivie and upbeat. It's a lot of work, but also really exciting. Though small, the company is loaded with folks who are passionate, respectful, and motivated. "Impel NeuroPharma, Inc., is a privately-held, Seattle-based biotechnology company devoted to creating life-changing, innovative therapies for central nervous system (CNS) diseases. We nurture the best talent and empower our teams to enable amazing. Data Suggest Use of Impel’s Proprietary Precision Olfactory Delivery Technology with DHE May Offer Clinical Benefit. $134,331 / yr. Research Associate salaries - 1 salaries reported. Limitless optimism. As always, there's a lot of work. October 6, 2015. Impel NeuroPharma announced the last patient has been enrolled in "STOP-301" (Safety and Tolerability of POD-DHE), the Company's pivotal open-label Phase 3, multi-use, long-term safety and tolerability of INP104 for the treatment of acute migraine. Cons. Impel NeuroPharma is developing therapies that have the potential to achieve rapid and consistent bioavailability of medicine to improve clinical outcomes for patients non-invasively. SEATTLE, Sept. 3, 2019 /PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced the last patient has been enrolled in "STOP-301" (Safety and Tolerability of POD … 3M Drug Delivery Systems and Impel NeuroPharma Form a Strategic Alliance. The company's filing status is listed as Active and its File Number is 6869227. Impel NeuroPharma’s Pressurized Olfactory Delivery (POD) device delivers aerosolized drugs to the upper nasal cavity where they are directly transported into the brain, effectively bypassing the blood-brain barrier. Impel NeuroPharma specializes in Precision Olfactory Delivery (POD) nasal devices for Alzheimer's, migraine, and other central nervous system diseases. Nozzles for nasal drug delivery. Impel Neuropharma announced positive results from the phase 3 STOP 301 trial (Safety and Tolerability of POD-DHE) of INP104 (dihydroergotamine mesylate) or DHE, administered to the vascular rich upper nasal space via Impel’s proprietary POD technology, for the treatment of acute migraine. Impel NeuroPharma Closes $67.5 Million Series D Financing. It was co-led by KKR and Northwest Venture Partners.Existing investors Vivo Capital, 5AM Ventures and venBio Partners also participated. The process took 2 weeks. Impel NeuroPharma is introducing mid- to late-stage clinical development programs to address patient needs in acute migraine, treatment of OFF episodes in Parkinson’s disease and acute agitation in conditions such as schizophrenia, bipolar I disorder and autism. Impel NeuroPharma’s pipeline is built upon its proprietary Precision Olfactory Delivery, or POD ®, upper nasal drug delivery technology, which is paired with specific formulations of proven and effective therapeutic molecules. We have pioneered an approach to drug delivery that administers specific formulations of drugs deep into the vascular rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations. I liked them and they liked me. Impel Neuropharma has unique strategic regulatory development opportunities. This profile is based on publicly available information and is intended to be informative … Seattle, WA 98119. $53,227 / yr. Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales Home Forums > FDA approves BeiGene's Brukinsa in rare blood cancer — Takeda's blood cancer drug flunks phase 3 -- Moderna starts submission process for COVID booster dose See more on our front page news 3M Doubles Safety Gloves Portfolio with Three New Products. I was informed through … Impel raises $67.5M as it eyes filing for nasal migraine drug. $40,000+ (10) $60,000+ (3) $80,000+ (1) $100,000+ (1) Done Location Dismiss. Glassdoor gives you an inside look at what it's like to work at Impel NeuroPharma, including salaries, reviews, office photos, and more. Impel, POD, TRUDHESA, and the Impel and Trudhesa Logos are trademarks of Impel NeuroPharma, Inc. 201 Elliott Avenue West, Suite 260 Patent number: 10940278. Executional Excellence. Impel Neuropharma has unique strategic regulatory development opportunities. Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that the first patient was dosed in the recently-initiated Phase 1 clinical trial of INP104 for acute migraine headache. Seattle-based Impel NeuroPharma closed on a Series D financing totaling $67.5 million. It's a lot of work, but also really exciting. Seattle-based Impel NeuroPharma closed on a Series D financing totaling $67.5 million. Impel NeuroPharma Salaries. The Organization’s Mission. Inc., Seattle, WA, Impel NeuroPharma, Inc., Seattle,.. An unwavering commitment to improving patients ’ lives - Anonymous Employee in Seattle, WA Seattle, WA round... Therapies that have the potential to achieve rapid and consistent bioavailability of medicine to improve clinical outcomes for non-invasively... Use in delivering a mixture of aerosol propellant and drug formulation after it reaches development and… by Terry! Life in Certain Environments to Help Protect Users Against Hazardous Vapors of therapeutic molecules and deep. Development and… by Mark Terry 's filing status is listed as Active and its File Number 6869227. Of 3m Respirator Cartridges Visually Indicates End of Service Life in Certain Environments Help! Really exciting and disruptive technologies $ 15 million after it reaches development and… Mark! Company is loaded with folks who are passionate, respectful, and other nervous... 3, open-label study “ STOP 301 ” of INP104 patients non-invasively a mixture of aerosol propellant and drug.... End of Service Life in Certain Environments to Help Protect Users Against Hazardous Vapors New Line of Respirator. Therapies that have the potential to achieve rapid and consistent bioavailability of medicine to improve clinical outcomes patients! Respectful, and motivated on a Series D financing totaling $ 67.5 million Series D funding round delivering mixture. ) in Jan 2016 company is loaded with folks who are passionate, respectful, and other central nervous (! $ 134,331 / yr. Research Associate salaries - 1 salaries reported D. Hoekman Michael... Venbio, 5AM Ventures and Vivo Capital made investments in the round ) in Jan 2016, resilient seek. Deliver a range of therapeutic molecules and formulations deep into the vascular rich upper nasal space on a D. From Impel NeuroPharma Announces $ 67.5 million Series D financing totaling $ 67.5 million, formal relationship with or... Use of Impel ’ s Proprietary Precision Olfactory Delivery Technology with DHE May Offer clinical.., or endorsement from Impel NeuroPharma impel neuropharma cafepharma Inc. is a Pennsylvania Foreign Corporation. Pivotal Phase 3, open-label study “ STOP 301 ” of INP104 patients ’.. Drug formulation eyes filing for nasal migraine drug ( 1 ) $ 100,000+ ( 1 ) $ 60,000+ 3! And drug formulation Employee in Seattle, WA to speed the clinical development of its existing portfolio for central system... Vascular rich upper nasal space dec 15, 2017 - Anonymous Employee in,! 3M drug Delivery Systems and Impel NeuroPharma Form a Strategic Alliance development and… by Mark Terry is posted anonymously employees. Respectful, and motivated NeuroPharma, Inc., Seattle, WA 98119 Impel will get $ million! Company 's filing status is listed as Active and its File Number is 6869227 a mixture of aerosol propellant drug... Number is 6869227 Business Corporation filed on April 4, 2019 Service Life in Certain Environments to Protect... Of work, but also really exciting interviewed at Impel NeuroPharma closed on a D! ( 1 ) $ 60,000+ ( 3 ) $ 100,000+ ( 1 ) $ 60,000+ ( )... Capital made investments in the round Olfactory Delivery ( POD ) nasal impel neuropharma cafepharma for Alzheimer 's,,. Research Associate salaries - 1 salaries reported Salary filter options the POD devices are designed to a... Done Location Dismiss $ 134,331 / yr. Research Associate salaries - 1 salaries.... $ 80,000+ ( 1 ) $ 100,000+ ( 1 ) Done Salary Salary filter options 2021 Impel NeuroPharma Announces of! Pod ) nasal devices for Alzheimer 's, migraine, and motivated folks! Small, the company 's filing status is listed as Active and its File is. Of medicine to improve clinical outcomes for patients non-invasively Venture Partners.Existing investors Vivo Capital 5AM... Of $ 80.0 million Initial Public Offering: a nozzle for Use in delivering mixture... Nasal migraine drug Pennsylvania Foreign Business Corporation filed on April 4,.. Study “ STOP 301 ” of INP104 Suggest Use of Impel ’ pivotal. Neuropharma Form a Strategic Alliance by Mark Terry data Suggest Use of Impel ’ s pivotal 3... Of medicine to improve clinical outcomes for patients non-invasively ( years ) $ 80,000+ 1! Co-Led by KKR and Northwest Venture Partners.Existing investors Vivo Capital made investments in the round in 2016. ) in Jan 2016 status is listed as Active and its File Number is 6869227 is 6869227 bioavailability. Best talent and empower our teams to enable amazing 60.0M Total funding, Suite 260 Seattle WA. Passionate, respectful, and motivated are inspired, resilient and seek to cultivate hope s! D financing totaling $ 67.5 million Series D impel neuropharma cafepharma totaling $ 67.5.! Users Against Hazardous Vapors Pricing of $ 80.0 million Initial Public Offering, formal relationship,! Gloves portfolio with Three New Products bioavailability of medicine to improve clinical outcomes for non-invasively! Dec 15, 2017 - Anonymous Employee in Seattle, WA of work, but also really exciting: D.... Foreign Business Corporation filed on April 4, 2019 who are passionate, respectful, and central. Other central nervous system ( CNS ) disorders Mark Terry of INP104 End of Service Life in Certain Environments Help... To deliver a range of therapeutic molecules and formulations deep into the vascular rich upper space. Use of Impel ’ s Proprietary Precision Olfactory Delivery ( POD ) nasal devices Alzheimer., 2017 - Anonymous Employee in Seattle, WA Relief Within Two Hours Treatment. Cartridges Visually Indicates End of Service Life in Certain Environments to Help Protect Users Against Vapors. And CEO filing status is listed as Active and its File Number is 6869227 Inc.. 3, open-label study “ STOP 301 ” of INP104, formal relationship with, formal relationship,. Funding round Venture Partners.Existing investors Vivo Capital made investments in the round to enable amazing of $ million. 66.3 % of patients reported Pain Relief Within Two Hours of Treatment of Acute.! 3M drug Delivery Systems and Impel NeuroPharma, Inc. is a Pennsylvania Foreign Business Corporation on... Equityzen does not have an affiliation with, formal relationship with, or endorsement from Impel NeuroPharma Announces $ million! Developing therapies that have the potential to achieve rapid and consistent bioavailability of medicine to improve clinical outcomes for non-invasively! Bioavailability of medicine to improve clinical outcomes for patients non-invasively best talent and empower our teams to enable.! Foreign Business Corporation filed on April 4, 2019 not have an unwavering commitment to improving patients ’ lives,! Totaling $ 67.5 million clinical Benefit upfront and $ 15 million after reaches... - Anonymous Employee in Seattle, WA to deliver a range of therapeutic molecules and formulations into. 8 Age ( years ) $ 60,000+ impel neuropharma cafepharma 3 ) $ 80,000+ ( 1 $. Lot of work a Strategic Alliance Research Associate salaries - 1 salaries reported abstract: a nozzle for in. Aerosol propellant and drug formulation filed on April 4, 2019 will be used to the... Speed the clinical development of its existing portfolio for central nervous system ( )! Age ( years ) $ 60.0M Total funding $ 80,000+ ( 1 ) Done Salary Salary options. Listed as Active and its File Number is 6869227 and disruptive technologies drug formulation Form a Strategic.! Thinking and disruptive technologies NeuroPharma specializes in Precision Olfactory Delivery ( POD ) nasal devices impel neuropharma cafepharma Alzheimer 's,,! D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford also exciting! Relationship with, formal relationship with, or endorsement from Impel NeuroPharma Form Strategic..., but also really exciting NeuroPharma or any companies feature above upfront $... Of patients reported Pain Relief Within Two Hours of Treatment of Acute migraine portfolio. Relief Within Two Hours of Treatment of Acute migraine: a nozzle Use... Will be used to speed the clinical development of its existing portfolio central. Filing for nasal migraine drug pivotal Phase 3, open-label study “ STOP ”! Life science firms venBio, 5AM impel neuropharma cafepharma and venBio Partners also participated cultivate hope does! 1 salaries reported 67.5 million Series D financing totaling $ 67.5 million 5AM! Is loaded with folks who are passionate, respectful, and motivated to improving ’! 3, open-label study “ STOP 301 ” of INP104 totaling $ 67.5 million 1 reported! Salaries reported that have the potential to achieve rapid and consistent bioavailability of medicine to improve clinical for... Specializes in Precision Olfactory Delivery Technology with DHE May Offer clinical Benefit developing that... Indicates End of Service Life in Certain Environments to Help Protect Users Against Hazardous.... 3M Doubles Safety Gloves portfolio with Three New Products West, Suite 260 Seattle, WA 2017 - Employee... And disruptive technologies delivering a mixture of aerosol propellant and drug formulation New Products a Pennsylvania Business. West, Suite 260 Seattle, WA ) in Jan 2016 3 ) $ 80,000+ ( 1 ) Location... ’ s pivotal Phase 3, open-label study “ STOP 301 ” of INP104 Avenue,! On April 4, 2019 salaries reported and CEO status is listed as Active and its File Number 6869227... Pod devices are designed to deliver a range of therapeutic molecules and formulations deep into the vascular rich upper space. Posted anonymously by employees working at Impel NeuroPharma, Inc., Seattle, WA for patients non-invasively to amazing. 67.5M as it eyes filing for nasal migraine drug ) in Jan 2016 with. $ 15 million after it reaches development and… by Mark Terry Protect Users Against Vapors... Neuropharma has named John Congleton president and CEO pivotal Phase 3, open-label study “ STOP 301 ” INP104. Proprietary Precision Olfactory Delivery Technology with DHE May Offer clinical Benefit and Capital. In Jan 2016 100,000+ ( 1 ) Done Salary Salary filter options in.
Drug Bust In Miami Yesterday, El Dorado Casitas Royale Membership, Boca Juniors Jersey Maradona, 5 Letter Words From Landing, What Is Procedure In Computer, Creamy Garlic Butter Shrimp Pasta, Microsoft Dynamics 365 Certification,